Uniqure Notches Bullish Initiation On Gene Therapy Prospects – Benzinga
Benzinga |
Uniqure Notches Bullish Initiation On Gene Therapy Prospects
Benzinga Uniqure's dominant gene therapy platform with an AAVS vector; its potential "best-in-class" lead gene therapy candidate AMT-061 for treating hemophilia B; and pipeline optionality for treating Huntington's and genetically driven heart disease create a … |
